Monoclonal Antibody Plus Cyclophosphamide in Treating Patients With Metastatic Cancer
NCT ID: NCT00002482
Last Updated: 2013-11-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
INTERVENTIONAL
1991-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: Phase I/II trial to study the effectiveness of monoclonal antibody and cyclophosphamide in treating patients with metastatic cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
NCT00002475
Cyclophosphamide Followed by Intravenous and Intraperitoneal Infusion of Autologous T Cells Genetically Engineered to Secrete IL-12 and to Target the MUC16ecto Antigen in Patients With Recurrent MUC16ecto+ Solid Tumors
NCT02498912
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
NCT00025181
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma
NCT00032045
Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors
NCT00052403
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
OUTLINE: Biological Response Modifier Therapy with Suppressor Cell Inhibition. Anti-CD3 Murine Monoclonal Antibody OKT3, MOAB OKT3; with Cyclophosphamide, CTX, NSC-26271.
PROJECTED ACCRUAL: At least 9 evaluable patients per diagnostic category will be required initially; if any response is seen during the dose-finding portion of the study, a total of 24 patients with that diagnosis will be entered.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
antibody therapy
biological therapy
muromonab-CD3
cyclophosphamide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: Not specified Surgery: Not specified
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
St. Vincent Medical Center - Los Angeles
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles L. Wiseman, MD, FACP
Role: STUDY_CHAIR
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
St. Vincent Medical Center - Los Angeles
Los Angeles, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SVMC-ONC-121
Identifier Type: -
Identifier Source: secondary_id
NCI-V90-0206
Identifier Type: -
Identifier Source: secondary_id
CDR0000077247
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.